Venture Capitalist Sheds Light On Market, Funding Options – Bio Korea (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
OSONG, South Korea - Venture capitalists are seeing the biggest returns from technology platforms or single-project financing, Hui-Hsing Ma, venture partner with TVM Capital told Bio Korea attendees.
You may also be interested in...
For Burgeoning Emerging Markets, All Business is Local
With growth slowing to a crawl in their largest markets, most major drug firms are focusing significant resources in emerging markets - now providing roughly one-third of the industry's growth, double its share two years ago
Bayer Schering Strengthens Presence In South Korea
SEOUL - Bayer Schering Pharma plans to upgrade its current seventh position in South Korea's pharma market to become one of three leading multinational companies in coming years, Bayer execs told reporters at a Nov. 27 press conference in Seoul
For Burgeoning Emerging Markets, All Business is Local
With growth slowing to a crawl in their largest markets, most major drug firms are focusing significant resources in emerging markets - now providing roughly one-third of the industry's growth, double its share two years ago